Compare IDEXX Laboratories, Inc. (IDXX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Visa Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Visa Inc trades at $360.56 (market cap $671.74B). The key difference: Visa Inc is far larger — about 14.5× IDEXX Laboratories, Inc.'s market cap, and Visa Inc pays a 0.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | V | |
|---|---|---|
Market Cap | $46.22B | $671.74B |
Sector | Health | Financials |
52-Week High | $766.68 | $370.47 |
52-Week Low | $526.44 | $295.52 |
Enterprise Value | $47.12B | $682.32B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Visa (V) trades at $360.00, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.32, and maintains robust fundamentals including a 50.78% net income margin and $20.06B net income for 2025. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for growth in digital payments.
The outlook for Visa remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Key risks include competitive pressures from fintech and regulatory scrutiny, but sustained revenue growth and high profitability support long-term investor appeal. The stock's valuation at a P/E of 30.88 reflects premium pricing justified by its market leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
